Redirecting Neurogenesis Using Drug-Loaded Exosomes Derived from Mesenchymal Stem Cells

Tech ID: 19A097

Competitive Advantages

  • Treats underlying destruction of nerve cells in neurological disorders
  • Stops further accumulation of toxic peptides
  • Biocompatible and biodegradable cell-derived nanoparticles

Summary

Our inventors have developed a novel stem cell-derived exosome, engineered at two different levels. At the first level stem cells are primed in an AD-related pro-inflammatory environment and exosomes are isolated. Results have shown that exosomes isolated from educated-stem cells have enhanced anti-inflammatory properties. However, these exosomes can only ensure the inhibition of the existing inflammation, and that’s why in the second step, they further modify these exosomes by incorporating retinoic acid that inhibits the production of toxic oligomers which is the main cause of inflammation in AD.

Inhibitory effect of stem cell-derived exosomes and educated stem cell derived exosomes on LPS-induced activation in microglia and astrocytes.

Desired Partnerships

  • License
  • Sponsored Research
  • Co-Development

 

Technology Transfer
TTOinfo@usf.edu
(813) 974-0994

Researcher(s)

Patents